Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Adlai Nortye Ltd.
Headquarters: Hangzhou, Zhejiang, China
Website: http://www.adlainortye.com
Year Founded: 2004
Status: Public
Industry Sector: N/A
CEO: N/A
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: N/A
Exchange/Ticker 1: NASDAQ:ANL
Exchange/Ticker 2: N/A
Latest Market Cap: $214,597,696
BioCentury | Apr 3, 2024
Management Tracks
Takeda vet Tanigaki named CEO of Aculys
Plus: Lonza names Wolfgang Wienand CEO, and updates from Verily, GSK, NewAmsterdam, Voyager, Adaptive, Ratio, Adlai Nortye and I-Mab
BioCentury | Sep 30, 2023
Finance
Sept. 29 Quick Takes: Adlai Nortye sinks after NASDAQ listing
Plus: NASH play Madrigal raises $500M, and updates from Regeneron, Thymmune, Harvard Medical School and more
BioCentury | Sep 15, 2023
Finance
Navigating China’s IPO options as STAR becomes no-go zone
New regulatory requirements make STAR market unattractive, will push China biotechs to Hong Kong, NASDAQ
BioCentury | Jul 27, 2023
Politics, Policy & Law
July 27 Quick Takes: Rachel King out of the running for BIO CEO
Plus: Cross-border oncology play Adlai Nortye launches NASDAQ bid and updates for Lilly’s tirzepatide, Enhertu, Merck’s pneumococcal vaccine, UroGen, Mersana and Biohaven
BioCentury | Jul 15, 2021
Regulation
July 15 Quick Takes: FDA panel rebuffs FibroGen CKD program; plus PAQ, Galapagos, Adlai Nortye and Ablynx-LabGenius
In light of concerns over roxadustat’s cardiovascular safety risks, FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 13-1 against approval of the oral HIF-PH inhibitor to
Items per page:
1 - 5 of 5